单克隆抗体C225对乳腺癌干细胞的抑制作用

›› 2009, Vol. 29 ›› Issue (11): 1311-.

单克隆抗体C225对乳腺癌干细胞的抑制作用

史亚飞¹, 黄明主², 张凤春², 张雁云³, 曹明智¹

1. 青岛大学医学院附属医院乳腺外科, 青岛 266003；2. 上海交通大学医学院仁济医院肿瘤科, 上海 200127；3. 中国科学院上海生命科学研究院/上海交通大学医学院健康科学研究所免疫学联合实验室, 上海 200025

出版日期:2009-11-25 发布日期:2009-11-24
通讯作者: 曹明智, 电子信箱: caomingzhi1102@yahoo.com.cn；张凤春, 电子信箱: fczhang2004@163.com。
作者简介:史亚飞（1979—）, 女, 硕士生；电子信箱: jysyf@sina.com。
基金资助:
山东省卫生厅课题（HW025）；上海市教委基金(J50208)；国家自然科学基金(30670798)；上海市浦东新区社会发展局卫生科技项目（DW2007D-4）

Inhibition effects of monoclonal antibody C225 on breast cancer stem cells

SHI Ya-fei¹, HUANG Ming-zhu², ZHANG Feng-chun², ZHANG Yan-yun³, CAO Ming-Zhi¹

1. Department of Galactophore, The Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, China；2. Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China；3. Joint Immunology Laboratory, Institute of Health Sciences, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences &|Shanghai Jiaotong University School of Medicine, Shanghai 200025, China

Online:2009-11-25 Published:2009-11-24
Supported by:
The Health Department of Shandong Province Foundation, HW025; Shanghai Education Committee Foundation,J50208; National Natural Science Foundation,30670798; Shanghai Pudong Medical Science Foundation, DW2007D-4

摘要/Abstract

摘要：

目的研究表皮生长因子受体(EGFR)的单克隆抗体西妥昔单抗(C225)对乳腺癌细胞系MCF-7中乳腺癌干细胞的抑制作用。方法 MTT法检测C225对MCF-7细胞增殖的影响。将MCF-7进行微球体培养，根据培养液中是否加入表皮生长因子(EGF)和C225分为对照组、C225组、EGF组、EGF+ C225组；培养13 d，观察四组微球体形成大小及数量，计算微球体形成率(MFE)；流式细胞术检测微球体细胞及常规培养MCF-7中CD44⁺CD24^－细胞比例。结果 MCF-7细胞增殖抑制率随C225质量浓度的增加而上升。与对照组比较，C225组微球体体积明显减小，且MFE和微球体中CD44⁺CD24^－细胞比例明显降低，分别为(0.61±0.04)% vs (1.44±0.09)% (P<0.01)和(3.50±0.29)% vs (9.07±0.52)% (P<0.01)。与EGF组比较，EGF+C225组微球体体积明显减小，且MFE和微球体中CD44⁺CD24^－细胞比例明显降低，分别为(0.68±0.04)% vs (1.61±0.05)% (P<0.01)和(4.00±0.58)% vs (10.47±0.79)% (P<0.01)。常规培养MCF-7中CD44⁺CD24^－细胞比例为（2.03±0.15）%，与EGF组和对照组比较差异有统计学意义（P<0.01）。EGF组与对照组微球体形成大小、MFE以及微球体中CD44+CD24－细胞比例的比较，差异均无统计学意义（P>0.05）。结论 C225对MCF-7中CD44⁺CD24^－细胞有明显抑制作用。

关键词: 乳腺癌, 干细胞, 微球体, 表皮生长因子受体, 单克隆抗体, C225

Abstract:

Objective To explore the inhibition effects of epidermal growth factor receptor (EGFR) antagonist monoclonal antibody cetuximab (C225) on breast cancer stem cells in human breast cancer cell line MCF-7. Methods The effects of C225 on the proliferation of breast cancer cell line MCF-7 were detected by MTT assay. MCF-7 cells were cultured to generate primary mammospheres, and were divided into control group, C225 group, epidermal growth factor (EGF) group and EGF+C225 group according to whether or not the culture media contained exogenous EGF and C225. Thirteen days after culture, the volume and number of mammospheres of these four groups were observed, and mammosphere-forming efficiency (MFE) was calculated. The percentages of CD44⁺CD24^-cells in mammospheres of these four groups and in routinely cultured MCF-7 cells were determined by flow cytometry. Results The inhibition rate on MCF-7 cells increased with the concentration of C225. Compared with control group, the volume of mammospheres in C225 group significantly decreased, and MFE and percentages of CD44⁺CD24^-cells in mammospheres significantly decreased [(0.61±0.04)% vs (1.44±0.09)%, P<0.01; (3.50±0.29)% vs (9.07±0.52)%, P<0.01]. Compared with EGF group, the volume of mammospheres in EGF+C225 group significantly decreased, and MFE and percentages of CD44⁺CD24^-cells in mammospheres significantly decreased [(0.68±0.04)% vs (1.61±0.05)%, P<0.01; (4.00±0.58)% vs (10.47±0.79)%, P<0.01]. The percentage of CD44⁺CD24^-cells in routinely cultured MCF-7 cells was (2.03±0.15)%, and was significantly different from those in EGF group and control group (P<0.01). There was no significant difference in volume of mammospheres, MFE and percentage of CD44⁺CD24^-cells in mammospheres between EGF group and control group (P>0.05). Conclusion C225 has significant inhibition effects on CD44⁺CD24^-cells in MCF cells.

Key words: breast cancer, stem cells, mammoshpere, epidermal growth factor receptor, monoclonal antibody, C225

史亚飞, 黄明主, 张凤春, 等. 单克隆抗体C225对乳腺癌干细胞的抑制作用[J]. , 2009, 29(11): 1311-.

SHI Ya-fei, HUANG Ming-zhu, ZHANG Feng-chun, et al. Inhibition effects of monoclonal antibody C225 on breast cancer stem cells[J]. , 2009, 29(11): 1311-.

[1]	张海燕, 储晓英. 非阿片类镇痛药应用在全身麻醉喉罩置入的乳腺癌保乳手术中的可行性[J]. 上海交通大学学报(医学版), 2021, 41(5): 637-641.
[2]	张佳玲, 张凤春, 徐迎春. 乳腺癌脑转移系统治疗的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(5): 671-677.
[3]	孙潇智, 李爽, 金颖, 廖兵. 酶消化细胞团块法对人胚胎干细胞中OCT4与SOX2蛋白水平的影响[J]. 上海交通大学学报(医学版), 2021, 41(4): 413-420.
[4]	颜佳扬, 冯耘, 瞿介明. 干细胞治疗急性呼吸窘迫综合征的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(4): 554-558.
[5]	赵艳娜, 邱荣, 沈南, 唐元家. 构建诱导型CRISPR/Cas9系统用于小鼠免疫细胞基因功能研究[J]. 上海交通大学学报(医学版), 2021, 41(3): 297-301.
[6]	李高扬, 姜霁峰, 刘传绪, 张文皓, 朱杨, 马玉杰, 陶荣. 安罗替尼治疗难治性自然杀伤/T细胞淋巴瘤的有效性与安全性的探索性研究[J]. 上海交通大学学报(医学版), 2021, 41(2): 196-201.
[7]	赵晓军, 乔志刚, 梁挺宇, 安艳玲. 乳腺癌易感基因1蛋白在脑胶质瘤中的表达及对替莫唑胺敏感性的影响[J]. 上海交通大学学报(医学版), 2021, 41(1): 118-122.
[8]	李艳花, 闫亚平, 刘晓琴, 席国萍, 宋国斌, 肖保国, 马存根. 法舒地尔联合过表达趋化因子受体5的间充质干细胞对实验性自身免疫性脑脊髓炎的治疗作用[J]. 上海交通大学学报(医学版), 2021, 41(1): 35-41.
[9]	陈思，刘春良，赵倩，孙海鹏，刘云霞. 基于生存分析的生物信息学方法筛选乳腺癌枢纽基因和关键通路[J]. 上海交通大学学报（医学版）, 2020, 40(3): 294-.
[10]	叶欣，周晓云，杨莉，王杰，何奇. 不同年龄范围界定下的年轻乳腺癌患者的临床病理特征及预后分析[J]. 上海交通大学学报（医学版）, 2020, 40(3): 351-.
[11]	朱正阳1, 2，王成3，姜辰一1，赵福军1, 3, 4. RNA N6- 甲基腺嘌呤异常修饰影响肿瘤干细胞促进恶性肿瘤发生、发展的研究进展[J]. 上海交通大学学报（医学版）, 2020, 40(3): 385-.
[12]	朱屿倩，吴凌云. m6A甲基化修饰在血液系统恶性肿瘤中的作用研究进展[J]. 上海交通大学学报（医学版）, 2020, 40(3): 396-.
[13]	程龙1，徐五琴2，张鹏1，黄建军1，李小宁1. 下调miR-27a表达对三阴乳腺癌细胞增殖、迁移和侵袭的影响[J]. 上海交通大学学报（医学版）, 2020, 40(2): 188-.
[14]	崔雅琦，白玉冰，许怡晨，谭心辰，李梦莹，贾浩. 脂肪来源的间充质干细胞及外囊泡促成骨分化的研究进展[J]. 上海交通大学学报(医学版), 2020, 40(12): 1672-1676.
[15]	戴尅戎. 非扩增性干细胞治疗理念的形成及其应用前景[J]. 上海交通大学学报(医学版), 2020, 40(10): 1318-1320.